Opioid

Pain Medicine Experts Recommend Monitoring, Education for All Opioid Medicines

American Academy of Pain Medicine Submits Comments on REMS; Leaders in Pain Research and Treatment Available to Media to Discuss Abuse, Diversion, and Pain Treatment GLENVIEW, Ill., May 27 /PRNewswire/ -- As the U.S. Food and Drug Administration (FDA) conducts public hearings this week on Ri...

Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes

-Here to Help(TM), a new support program designed to improve treatment outcomes for patients dependent on prescription painkillers or heroin, from Reckitt Benckiser Pharmaceuticals- RICHMOND, Va. , May 18 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals has launched Here to Help(TM), an u...

Nausea Drug Shows Promise Against Opioid Addiction

Ondansetron relieves withdrawal symptoms without side effects, early study shows WEDNESDAY, Feb. 18 (HealthDay News) -- A drug currently used to treat nausea can prevent symptoms of withdrawal from illegal and prescription opioid drugs such as heroin, morphine and codeine, a new study ...

Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire

CHARLESTON, S.C., Feb. 12 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced preliminary findings from its development and testing of an Opioid Symptoms ...

New guidelines for prescribing opioid pain drugs published

GLENVIEW, IL, Feb. 10, 2009 A prestigious panel of pain-management experts representing the American Pain Society (APS) www.ampainsoc.org and the American Academy of Pain Medicine (AAPM) has published the first comprehensive clinical practice guideline to assist clinicians in prescribing potent...

New Guidelines for Prescribing Opioid Pain Drugs Published

GLENVIEW, Ill., Feb. 10 /PRNewswire/ -- A prestigious panel of pain-management experts representing the American Pain Society (APS) www.ampainsoc.org and the American Academy of Pain Medicine (AAPM) has published the first comprehensive clinical practice guideline to assist clinicians in prescri...

New guideline for prescribing opioid pain drugs published

A national panel of pain management experts representing the American Pain Society (APS) and the American Academy of Pain Medicine (AAPM) has published the first comprehensive, evidence-based clinical practice guideline to assist clinicians in prescribing potent opioid pain medications for patient...

TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA

BLUE BELL, Pa., Nov. 13 /PRNewswire/ -- TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release stro...

DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology

CUPERTINO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX ) today reported that Pain Therapeutics (Nasdaq: PTIE ), its licensee, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioi...

Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL MONTREAL, March 6 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has started its first EDAC...

More>>

Opioid in Medical Technology

One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

TROY, N.Y., May 8 /PRNewswire-USNewswire/ -- For more than 10 years, Mark Wentland, professor of chemistry and chemical biology at Rensselaer Polytechnic Institute , led a Rensselaer team in the discovery of a family of novel opioid receptor compounds with the potential to treat nervous system di...

Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments

Addiction can lead to hospitalization and drug withdrawal CHICAGO, May 15, 2007 /PRNewswire/ -- A new survey of hundreds of migraine patients and physicians commissioned by the National Headache Foundation and conducted by Harris Interactive shows that 20 percent of migraine patients are currently...

Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential for the Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for the treatment of neurological conditions, announce...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company through its Pharmaceuticals Division, this week presented positive results of a pharmacokinetic study of its investigational abuse-deterrent, extended-release opioid at the 2...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...s to improve and enable molecules. The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist dr...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

...tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) Gel, a nonsteroid...

Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians

...mism. Addiction to and abuse of prescription opioid drugs are prevalent, and they exact an immense tol...g Cancer Center, New York, in "Issues in Long-Term opioid Therapy: Unmet Needs, Risks, and Solutions." opioid drugs have been used by humans for thousands of ye...

Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)

...t candidates and other innovative abuse deterrent technologies. Acura and King jointly developed Acurox(R) Tablets and are developing three additional opioid analgesic product candidates utilizing Aversion(R) Technology pursuant to a 2007 License, Development and Commercialization Agreement. About Kin...

AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

...s(TM) for the management of acute post-operative pain in patients requiring opioid analgesia during hospitalization. Compared to placebo, patients receiving A...ly for oral transmucosal absorption. Sufentanil is a high therapeutic index opioid approved for intravenous and epidural administration. Although the analgesi...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

...for ACUROX(R) and EMBEDA(TM) (ALO-01), two novel opioid analgesic formulations that are in development, at... Pain EMBEDA(TM) Capsules (ALO-01), a novel opioid formulation, contain pellets of an extended-releas...t associated with clinically observable effects of opioid withdrawal or reduction of pain relief. Pha...

Opioid in Medical Dictionary

Peripheral

...heral nerve stimulator plus ON-Q Cbloc ... Tolerance at Peripheral opioid Receptors: The first step in pain treatment is ... opioid Secretion and Peripheral Pain Control ... Can you reverse the effects...

Pain medications

... medications are useful for acute pain , they ... Home > Drugs, Police & the Law > Pain Medication > Manage Subscriptions ... opioid analgesics ( medication which reduces or relieves pain ) are some of the ... (Redirected from Pain medication ) Jump to: navigation, search "...

Chronic Pain

...ere any treatment? ... Chronic pain is widely believed to represent disease itself. ... More serious chronic pain conditions may require opioid drugs (narcotics) ... Chronic pain persists over a long period of time and is resistant to most medical treatments. ... Patient Discussions: ...

Opioid in Biological News

How does the opioid system control pain, reward and addictive behavior?

The opioid system controls pain, reward and addictive behaviors. Opioids exert their pharmacological actions through three opioid receptors, mu, delta and kappa whose genes have been cloned (Oprm, Oprd1 and Oprk1, respectively). Opioid receptors in the brain are activated by a family of endogenous...

Key Trigger Of Opioid Withdrawal Symptoms Found

Researchers have discovered an important chemical in the brain's neuronal machinery that triggers some of the withdrawal symptoms of opioid drugs like morphine and heroin. They believe that drugs to inhibit the chemical--called a transporter--could relieve some of the early physical symptoms of ...

Regulation of cell proliferation by the OGF-OGFr axis is dependent on nuclear localization signals

...of Medicine, Hershey, Pennsylvania have discovered that the efficacy of the opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically important antitumor ag...l Biology and Medicine said "Zagon and colleagues have discovered that the opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically important antitumor ag...

Lab study shows methadone breaks resistance in untreatable forms of leukemia

...hat methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukem...any in the 1930s, is a low cost agent that acts on opioid receptors, and thus is used as an opioid substitute to treat addiction. Scientists have fou...

Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway

... modifier with potent antiviral and antitumor activity, is dependent on the opioid Growth Factor (OGF)-OGF receptor (OGFr) axis for its action. This discover... work, Zagon and colleagues have identified the role of met-enkephalin (the opioid growth factor OGF) and the OGF receptor in regulating cell proliferation. T...

Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's

...edical Center "NBD Peptides in a Non-Human Primate Model of Parkinson's Disease" Yvette F. Tache, PhD, University of California, Los Angeles "Mu opioid Receptors as a Drug Target for Treating Motor Fluctuations in PD" Malu G. Tansey, PhD, University of Texas Southwestern Medical Center "Dopaminer...

The myth of runner's high revisited with brain imaging

... TUM and who is now in charge of the Functional Neuroimaging Group at the Dept. of Radiology, University Hospital Bonn. And further: 'Respectively the opioid receptor binding of the [18F]FDPN decreases, since there is a direct competition between endorphins in the brain and the injected ligand'. By comparin...

Biophysical Society announces 2008 International Travel Awards

...nserved Chromatin Protein. Slawomir Filipek, International Institute of Molecular and Cell Biology, Warsaw, Poland, Agonist/Antagonist Sensor in opioid Receptors-Molecular Modeling Study. Mark R. Fowler, University of Glasgow, United Kingdom, Spatially Restricted Ca2+ Transients Reflect Release...

'Runner's high' may also strengthen hearts

... increased expression of several genes involved in opioid pathways that appear to be critical in protecting ...ed rats. The researchers then showed that blocking opioid receptors completely eliminated these cardio-prote... with transient increases in expression of several opioid system genes in heart muscle, and changes in expre...

20th ECNP Congress 2007, Oct. 13-17, Vienna, Austria

...s opened the door for the development of new drugs. The influence of opioid receptors in the brain: The opioid system controls pain, reward and addictive behaviour. Brigitte Kieffer pres...

Opioid in Biological Technology

ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study

WILMINGTON, Del., July 15 /PRNewswire/ -- ParagonRx, a healthcare consulting leader in risk management and the appropriate use of drugs, has filed its interim analysis of a study that shows how its proprietary approach to risk management can help manufacturers of opioid drugs meet FDA standar...

Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications

Former Director of the Office of National Drug Control Policy to Moderate First Educational Webinar: When Good Medicines Become Bad Drugs FRAZER, Pa., Oct. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it is embarking on a national educational program design...

NeurogesX Reports Second Quarter 2009 Results

...also seeking business development partners to advance its acetaminophen and opioid prodrug product candidates. NGX-9674 and NGX-5752, novel prod...phen. NGX-6052, the most advanced molecule synthesized in NeurogesX' opioid prodrug platform, has been evaluated in proof of concept in vivo and in ...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

...s to improve and enable molecules. The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist dr...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

...tforms to improve and enable molecules. The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist dr...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

...tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and Voltaren(R) Gel, a nonsteroid...

Anesiva Receives NASDAQ Delisting Staff Determination Letter

...asty (TKA) at four to 48 hours after surgery. The trial also met its key secondary endpoint with Adlea demonstrating a highly significant reduction in opioid medication consumption compared to placebo (p=0.005). The Phase 3 TKA trial, known as ACTIVE-2, also showed that Adlea's safety profile of a...

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy

...hat MoxDuo(TM) IV will enable doctors to provide better pain relief with fewer side effects, getting patients on their feet earlier than with existing opioid pain medications." Following hip replacement surgery, 40 subjects will be randomised into MoxDuo(TM) IV or morphine IV groups over a two-part...

Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)

... About Caldolor Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in pa...

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer

...rms to improve and enable molecules. The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist dr...

Opioid in Biological Products

Rabbit Anti-mu Opioid Receptor splice variant Antibody, Unconjugated from ABR-Affinity BioReagents

Description: mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Company:ABR-Affinity BioReagents

Opioid in Biological Definition

Peptide

...ately. It has also been documented that when certain food proteins such as gluten , casein , egg protein and spinach protein are broken down, opioid peptides are formed. These peptides mimick the effects of morphine , and those who are unable to break them down will experience mental illness. The...

Peptide

...ately. It has also been documented that when certain food proteins such as gluten , casein , egg protein and spinach protein are broken down, opioid peptides are formed. These peptides mimick the effects of morphine , and those who are unable to break them down will experience mental illness. The...

Opioid in Biological Dictionary

Rhodopsin

... The European Bioinformatics Institute ... The rhodopsin -like GPCRs themselves represent ... Rhodopsin . EDG-1 sphingosine 1-phosphate receptor. opioid receptor ... A description of the current concept of the chromophores of vision ... HISTORICAL CONCEPT OF RHODOPSIN . RECENT PROPOSALS BASED ON ...

Polypeptide

... 4.3 Pancreatic polypeptide -related peptides. 4.4 opioid peptides. 4.5 Calcitonin peptides ... A polypeptide is a single linear chain of amino acids. ... Amylin, or Islet Amyloid Polypeptide (IAPP...